Related Experiment Video
Updated: May 26, 2026
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Fidaxomicin: in Clostridium difficile infection
1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
Drugs
|December 7, 2011
Summary
Fidaxomicin effectively treats Clostridium difficile infection with lower recurrence rates than vancomycin. This macrocyclic antibacterial shows a favorable safety profile, offering a new option for C. difficile infection management.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Clostridium difficile infection (CDI) is a significant healthcare concern.
- Existing treatments like vancomycin have limitations, including recurrence.
- Fidaxomicin is a novel macrocyclic antibacterial with targeted activity.
Purpose of the Study:
- To evaluate the efficacy and safety of fidaxomicin compared to vancomycin for treating CDI.
- To assess fidaxomicin's impact on CDI recurrence rates.
Main Methods:
- Two randomized, double-blind, phase III clinical trials were conducted.
- Patients received oral fidaxomicin (200 mg every 12 hours) or oral vancomycin (125 mg every 6 hours) for 10 days.
- Clinical cure rates, recurrence rates, and global cure rates were primary endpoints.
Main Results:
- Fidaxomicin demonstrated non-inferiority to vancomycin in clinical cure rates.
- Fidaxomicin therapy was associated with significantly lower recurrence rates.
- Global cure rates were significantly higher with fidaxomicin compared to vancomycin.
Conclusions:
- Fidaxomicin is a safe and effective treatment for Clostridium difficile infection.
- Fidaxomicin offers a significant advantage over vancomycin in reducing CDI recurrence.
- Fidaxomicin presents a valuable therapeutic option for managing CDI.
Related Concept Videos
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...